Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: GlobalData
$125.00
Provider: GlobalData
$250.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Nattopharma ASA Announces Results of Study on MenaQ7 Brand Vitamin K2


Wednesday, 3 Apr 2013 03:01am EDT 

Nattopharma ASA announced results of a new study on its MenaQ-7T brand of Natural Vitamin K2 standardized to MK-7 content. In the human trial, MenaQ7T was shown to be a potent inhibitor of anticoagulant activity, an indicator of the protective benefits of natural K2 for vitamin k-dependent proteins. In this trial, vitamin K2 was shown to be more potent than K1. In the study the efficacy of menaquinone-7 (MK-7, brand name MenaQ7) was tested in healthy volunteers. The original vitamin K levels were decreased by giving them a daily dose of a vitamin K-antagonist (VKA). VKA treatment resulted in the production of undercarboxylated (i.e. inactive) forms of coagulation factors, osteocalcin and matrix Gla-protein (MGP). Subsequently the participants received increasing doses of MK-7, and it was monitored how the various proteins regained activity. 

Company Quote

11.0
-0.65 -5.58%
4:18am EDT